S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967708.07200.5a |
| _version_ | 1797281626833551360 |
|---|---|
| author | Meletios A. Dimopoulos Vania Hungria Atanas Radinoff Sosana Delimpasi Gabor Mikala Tamas Masszi Jian LI Marcelo Eduardo Capra Morio Matsumoto Neal Sule Mary LI Astrid Mckeown Wei He Shelley Bright Brooke Currie Julia Boyle Joanna Opalinska Katja Weisel |
| author_facet | Meletios A. Dimopoulos Vania Hungria Atanas Radinoff Sosana Delimpasi Gabor Mikala Tamas Masszi Jian LI Marcelo Eduardo Capra Morio Matsumoto Neal Sule Mary LI Astrid Mckeown Wei He Shelley Bright Brooke Currie Julia Boyle Joanna Opalinska Katja Weisel |
| author_sort | Meletios A. Dimopoulos |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:59:08Z |
| format | Article |
| id | doaj.art-9191e9fdb2564bc3afaf1af09b250cca |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:59:08Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-9191e9fdb2564bc3afaf1af09b250cca2024-03-03T03:25:45ZengWileyHemaSphere2572-92412023-08-017e072005a10.1097/01.HS9.0000967708.07200.5a202308003-00101S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)Meletios A. Dimopoulos0Vania Hungria1Atanas Radinoff2Sosana Delimpasi3Gabor Mikala4Tamas Masszi5Jian LI6Marcelo Eduardo Capra7Morio Matsumoto8Neal Sule9Mary LI10Astrid Mckeown11Wei He12Shelley Bright13Brooke Currie14Julia Boyle15Joanna Opalinska16Katja Weisel171 National and Kapodistrian University of Athens School of Medicine, Athens, Greece2 Department of Hematology, Clinica São Germano, Sao Paulo, Brazil3 University Hospital “St Ivan Rilski” EAD, Sofia, Bulgaria4 General Hospital Evangelismos, Athens, Greece5 South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary6 Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary7 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China8 Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil9 National Hospital Organization, Shibukawa Medical Center, Shibukawa, Japan10 GSK, Upper Providence, PA, United States10 GSK, Upper Providence, PA, United States11 GSK, Stevenage, England, United Kingdom12 GSK, Waltham, MA, United States10 GSK, Upper Providence, PA, United States13 GSK, Rockville, MD, United States14 GSK, London, United Kingdom10 GSK, Upper Providence, PA, United States15 University Medical Center of Hamburg-Eppindorf, Hamburg, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000967708.07200.5a |
| spellingShingle | Meletios A. Dimopoulos Vania Hungria Atanas Radinoff Sosana Delimpasi Gabor Mikala Tamas Masszi Jian LI Marcelo Eduardo Capra Morio Matsumoto Neal Sule Mary LI Astrid Mckeown Wei He Shelley Bright Brooke Currie Julia Boyle Joanna Opalinska Katja Weisel S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) HemaSphere |
| title | S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) |
| title_full | S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) |
| title_fullStr | S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) |
| title_full_unstemmed | S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) |
| title_short | S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3) |
| title_sort | s199 a phase 3 open label randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed refractory multiple myeloma dreamm 3 |
| url | http://journals.lww.com/10.1097/01.HS9.0000967708.07200.5a |
| work_keys_str_mv | AT meletiosadimopoulos s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT vaniahungria s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT atanasradinoff s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT sosanadelimpasi s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT gabormikala s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT tamasmasszi s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT jianli s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT marceloeduardocapra s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT moriomatsumoto s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT nealsule s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT maryli s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT astridmckeown s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT weihe s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT shelleybright s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT brookecurrie s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT juliaboyle s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT joannaopalinska s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 AT katjaweisel s199aphase3openlabelrandomizedstudyevaluatingtheefficacyandsafetyofsingleagentbelantamabmafodotinvspomalidomideplusdexamethasoneinrelapsedrefractorymultiplemyelomadreamm3 |